By InsightArea Editorial Team
DNA is not simply a long list of genes. It is folded and organized inside the cell, influencing which genes can interact with regulatory elements. New research suggests that a family of cancer-associated mutations can alter that organization through a protein called CTCF.
Weill Cornell Medicine’s account says the study was published in Nature on October 28, 2026. It used cell and animal models to examine mutations affecting the BAF complex, a group of proteins involved in regulating access to DNA. The findings point to potential research targets; they do not establish an approved therapy.
Why does DNA’s arrangement matter?
A cell contains many of the same genes as other cells in the body, yet different genes are active in different tissues. Regulatory proteins help determine which parts of DNA are accessible and which genes are switched on or off.
DNA also folds into loops and neighborhoods. Those physical arrangements influence which regulatory elements can contact a gene. Changing the arrangement can therefore change gene activity without changing the sequence of every affected gene.
What did the researchers observe?
According to Cornell, loss of BAF function in the models allowed CTCF to bind at many additional sites. This was associated with widespread changes in the three-dimensional organization of DNA and altered gene activity. The team investigated related mechanisms across several models rather than treating each tissue as a wholly separate question.
In animal models, removing CTCF reversed effects linked to the BAF mutations. Cornell also reports that the researchers examined patient data and observed associations involving CTCF disruption and outcomes. Associations in patient data are not proof that removing the protein would be a safe or effective treatment.
Why might one mechanism appear in different cancers?
Different tissues can share basic machinery for organizing DNA. A mutation in that machinery may therefore have effects in more than one setting. But cancers also differ in other mutations, environments and responses to treatment. A shared mechanism does not mean that one future drug would work for every person or cancer type.
Cornell identifies CTCF and partner complexes as candidates for further research. Targeting a protein with broad roles in normal cells could present safety challenges. Researchers would need to establish which cancers depend on the pathway and whether an intervention can affect tumors without unacceptable harm.
What comes next?
Further work can test how DNA organization changes, identify druggable steps and evaluate potential interventions in appropriate models. Clinical trials would be needed to determine safety and effectiveness in people.
The study is a useful reminder that cancer biology involves more than a list of mutated genes. The way the genome is packaged and accessed can influence which signals a cell receives—and that creates both opportunities and difficult questions for future treatment research.
For readers interested in tackling difficult goals, explore How to Do Hard Things.
Comments are closed.